Board Rules that Tribal Immunity is Unavailable to Avoid Inter Partes Review Challenge

26 February 2018 PTAB Trial Insights Blog

On Feb. 23, 2018, the Patent Trial and Appeal Board (“Board”) ruled an assertion of Tribal sovereign immunity would not avoid challenges to certain patents that had been assigned to the Saint Regis Mohawk Tribe (“the Tribe”). See Mylan Pharm., Inc. v. Saint Regis Mohawk Tribe, IPR2016-01127, Paper No. 130 (February 23, 2018).  In our earlier post entitled “Pharma Patents Assigned to Indian Tribe to Thwart Inter Partes Review” we reported that certain Orange Book-listed patents had been assigned to the Tribe, which licensed the patents back to the original assignee, in an effort to obtain dismissal of the pending inter partes reviews (“IPRs”) against those patents. 

As background, Mylan and others had joined in IPR challenges, with a consolidated hearing scheduled for September 2017. IPR2016-01127, Paper No. 130 at 2.  Less than a week before that hearing, counsel for the Tribe contacted the Board to notify them that the Tribe had acquired rights to the challenged patents and was seeking permission to file a motion to dismiss the proceedings based on the Tribe’s sovereign immunity. Id.  Thereafter, motion practice on the issue was authorized, including unprecedented permission by the Board authorizing third parties to file amicus briefs. Id. at 2-4.

The Board denied the Tribe’s motion on several grounds, the first of which was that the Board found no controlling precedent or any statutory basis for the application of tribal immunity to IPR proceedings. Id. at 7-10.  Notably, in coming to that conclusion, the Board specifically distinguished prior cases addressing “state sovereign immunity.” Id. at FN 4 (emphasis added).  The Board separately found the tribal immunity doctrine does not apply to IPR proceedings, and that “Courts have recognized only limited exceptions when a generally applicable federal statute,” such as those governing IPRs, “should not apply to tribes.” Id. at 11-13.  The PTAB also recently curtailed use of sovereign immunity as a defense against IPRs when the patent at issue has been enforced in patent litigation, as discussed in “Expanded PTAB Panel Finds Sovereign Immunity Waived By Patent Enforcement.”

In addition, and going a step further, the Board determined it could proceed even if participation of the Tribe was terminated, as the proceeding could continue with the original assignee as the “patent owner.” Id. at 18-19.  Going forward, the Board has ordered the parties to “coordinate their efforts” and to “file joint papers in these proceedings unless otherwise authorized by the Board.” IPR2016-01127, Paper No. 132 (February 23, 2018) at 3.

In that regard, the Board has now resumed the schedule of the proceedings that was previously suspended, has tentatively set the oral hearing for April 3, 2018, and adjusted the time for the final written decision to June 6, 2018 – exactly 1.5 years from the institution dates of the underlying proceedings. See 37 C.F.R. 42.100(c) (allowing extension of up to six months beyond normal one-year time to final written decision, consistent with 35 U.S.C. § 316(a)(11)).

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

The DOL Tries to Say Goodbye—And Seriously, We Mean It—to the 80/20 Rule for Tipped Employees
21 October 2019
Labor & Employment Law Perspectives
To Stalk or Not to Stalk . . . That Is the Question – Using Social Media for Applicant Review
21 October 2019
Labor & Employment Law Perspectives
New Patent Subject Matter Eligibility Updates Seeks Examination Predictability
21 October 2019
Legal News: Intellectual Property
Cryptocurrency in China is like BIG BROTHER in 1984!
20 October 2019
Internet, IT & e-Discovery Blog
PATH Summit 2019
18-20 December 2019
Arlington, VA
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.